



200 Sidney Street
Cambridge, MA 02139

Tel: 617-945-9626

www.serestherapeutics.com

March 16, 2020

Via EDGAR Transmission

Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Tim Buchmiller

**Re: Seres Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 9, 2020
Registration No. 333-237033**

Dear Mr. Buchmiller:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on March 18, 2020 at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Seres Therapeutics, Inc. (the "Company") or its counsel may request via telephone call to the staff. Please contact Peter Handrinis of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Wesley C. Holmes at (617) 948-6027, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.



SERES
THERAPEUTICS™

200 Sidney Street
Cambridge, MA 02139

Tel: 617-945-9626

www.serestherapeutics.com

Sincerely yours,

Seres Therapeutics, Inc.

By: /s/ Eric D. Shaff

Eric D. Shaff

President and Chief Executive Officer

cc: Peter N. Handrinos, Esq.
Wesley C. Holmes, Esq.